Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H11F3N2O |
| Molecular Weight | 328.2879 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CC2=C(C=CC(\C=C\C(=O)C3=CC=NC=C3)=N2)C=C1
InChI
InChIKey=IAJOMYABKVAZCN-AATRIKPKSA-N
InChI=1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H/b6-5+
| Molecular Formula | C18H11F3N2O |
| Molecular Weight | 328.2879 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4176 ng/mL |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACT-PFK-158 plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
18883 ng/mL |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACT-PFK-158 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3235 ng × h/mL |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACT-PFK-158 plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3298 ng × h/mL |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACT-PFK-158 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.4 h |
5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACT-PFK-158 plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.6 h |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACT-PFK-158 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:30:51 GMT 2025
by
admin
on
Mon Mar 31 23:30:51 GMT 2025
|
| Record UNII |
2HOK1JQ203
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2HOK1JQ203
Created by
admin on Mon Mar 31 23:30:51 GMT 2025 , Edited by admin on Mon Mar 31 23:30:51 GMT 2025
|
PRIMARY | |||
|
PFK-158 FREE BASE
Created by
admin on Mon Mar 31 23:30:51 GMT 2025 , Edited by admin on Mon Mar 31 23:30:51 GMT 2025
|
PRIMARY | MedKoo CAT NO.: 206166, CAS NO.: 1462249-75-7Description: PFK-158, also known as ACT-PFK-158, is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. (Last updated: 3/22/2016)Synonym: PFK158, PFK 158, PFK158, ACTPEK158. | ||
|
1462249-75-7
Created by
admin on Mon Mar 31 23:30:51 GMT 2025 , Edited by admin on Mon Mar 31 23:30:51 GMT 2025
|
PRIMARY | |||
|
71730058
Created by
admin on Mon Mar 31 23:30:51 GMT 2025 , Edited by admin on Mon Mar 31 23:30:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: University of Louisville; Developer: Advanced Cancer Therapeutics; Class: Antineoplastic, Small molecule; Mechanism of Action: Glucose modulator, PFKFB3 protein inhibitor
Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Solid tumours; Most Recent Events: 01 Mar 2014 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02044861), 22 Jan 2014 Preclinical trials in Solid tumours in USA (IV), 22 Jan 2014 Advanced Cancer Therapeutics plans a phase I trial for Solid tumours (second-line therapy or greater, late-stage disease) in USA (NCT02044861)
|
